ArticleBrain sciences2022
The NXDC-MEN-301 Study on 5-ALA for Meningiomas Surgery: An Innovative Study Design for the Assessing the Benefit of Intra-Operative Fluorescence Imaging.
Article in Brain sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04305470 (A Phase 3 Multicenter Study of Gleolan), which is not on this map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent Meningiomas
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- 5-Aminolevulinic acid as an emerging radiosensitizer for radiodynamic therapy in solid tumors: a systematic review of available data and clinical potential.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Pooled it
- Efficacy and safety of 5-aminolevulinic acid in meningioma resection: a systematic review and meta-analysis.Neurosurgical review · 2025Pooled it
- The Future of Clinical Trials in Surgical Neuro-Oncology Is Bright.Brain sciences · 2025Article
- Fluorescence and immune-cell infiltration of nonneoplastic, postbrachytherapy brain tissue in 5-ALA-guided resection of recurrent anaplastic meningioma: illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- Fluorescence guidance in skull base surgery: Applications and limitations - A systematic review.Brain & spine · 2024Review
- Toward standardized brain tumor tissue processing protocols in neuro-oncology: a perspective for gliomas and beyond.Frontiers in oncology · 2024Article
- Second-Generation Wide-Field Visualization Devices for 5-ALA-Induced Fluorescence and Concepts for Validation in Neurosurgery-A Systematic Review.Neurosurgery practice · 2023Review
- 5‑aminiolevulinic acid induces a radiodynamic effect with enhanced delayed reactive oxygen species production under hypoxic conditions in lymphoma cells: AnExperimental and therapeutic medicine · 2023Article
- Intraoperative molecular imaging: 3rd biennial clinical trials update.Journal of biomedical optics · 2023Review
- Meningiomas with CNS invasion.Frontiers in neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
background5-aminolevulinic acid (5-ALA; Gleolan
methodsAll patients with suspected meningioma (all grades) receive Gleolan
resultsAs of May 2022, 88 patients have completed the study. No adverse safety signal has been detected.
conclusionsPreliminary data confirm the feasibility of our study design. Accrual is targeted for completion in the third quarter of 2022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.